BMS temporarily expands Board with three new additions
pharmafile | February 23, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | BMS, Bristol-Myers Squibb
Bristol-Myers Squibb has bolstered its Board of Directors with the appointment of three Directors, a move which temporarily expands its membership to 14 until the company’s annual meeting on 2 May.
BMS has been joined by Robert J Bertolini, Matthew W Emmens, and Theodore R Samuels.
Former President and CFO of eye healthcare company Bausch & Lomb, Bertolini currently also serves as a board member for Actelion Pharmaceuticals and Charles River Laboratories. Of his appointment, he stated: “I am pleased to be joining the Board during a period of innovation and scientific discovery. I look forward to joining my fellow directors and the management team in helping Bristol-Myers Squibb with the compelling opportunities ahead.”
Samuels brings 35 years of financial industry experience to the board, currently serving the same role at Perrigo Company and Stamps.com. In the past, he was President of Capital Guardian Trust Company. “Bristol-Myers Squibb is widely regarded as an innovator and a leader with a strong portfolio of assets that will help drive value for shareholders,” he remarked. “I look forward to working with my colleagues on the Board to continue advancing the company’s important mission.”
Finally, Emmens is the ex-Chairman, President and CEO of Vertex Pharmaceuticals, and the previous Chairman and CEO of Shire and President and CEO of Astra Merck. He has served in the industry for over 40 years. “I am honoured to join the Bristol-Myers Squibb Board and to work alongside some of the great minds in science and medicine,” he said. “With a diverse portfolio and a strong pipeline, I am confident that Bristol-Myers Squibb will continue to find solutions for patients with high unmet medical needs.”
On the appointment of the three new members, Chairman of the Board Lamberto Andreotti commented: “I am pleased to welcome Bob, Matt and Ted to the Board, and know that their unique skill sets and experience will be invaluable to the company going forward. As I announced in December, I will be retiring as chairman, effective 2 May, 2017. I am happy to be leaving with such a strong Board in place and am confident Bristol-Myers Squibb has a bright future.”
Related Content
Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …
BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …
BMS shares new research and development plans at the company’s R&D day
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …
